Loading clinical trials...

Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate | Clinical Trials | Clareo Health

COMPLETED

Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate

NCT01955369•Klinikum Ludwigshafen

Summary

There is a lack of prospective and population-based epidemiological data on amyotrophic lateral sclerosis in Germany so far. The purpose of this registry is to investigate the incidence, course and phenotypic variety of ALS in Rhineland-Palatinate, a South-West German state of about 4 million inhabitants.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•diagnosis of amyotrophic lateral sclerosis according to revised El Escorial criteria
•minimum of 18 years
•minimum of 6 months of residency in Rhinelnad-Palatinate

Exclusion Criteria

•patients below 18 years
•ALS patients outside Rhineland-Palatinate

Locations (1)

Dept. of Neurology, Klinikum Ludwigshafen

Ludwigshafen, Germany

Key Dates

Start Date

October 1, 2009

Primary Completion Date

September 1, 2012

Completion Date

September 1, 2015

Last Updated

May 19, 2016

Enrollment

200

ACTUAL participants

Conditions

Amyotrophic Lateral Sclerosis

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003

Amyotrophic Lateral Sclerosis

View study

RECRUITING

Intermuscular Coherence as a Biomarker for ALS

NCT05104710

Amyotrophic Lateral Sclerosis

View study

RECRUITINGNA

Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

NCT07357428

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 19, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate

Inclusion Criteria

Exclusion Criteria

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Intermuscular Coherence as a Biomarker for ALS

Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

UPenn Observational Research Repository on Neurodegenerative Disease

Control Cohort CTRL COH

ASSESS ALL ALS Study